Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: Involvement of ATP-sensitive K+ channels

Neuropharmacology

Volumn 51, Issue 2, 2006, Pages 182-190

  Kawabata, Atsufumi ^a   Kawao, Naoyuki ^a   Hironaka, Yoshimi ^a   Ishiki, Tsuyoshi ^a   Matsunami, Maho ^a   Sekiguchi, Fumiko ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Adjuvant; Allodynia; Analgesia; Bisphosphonate; Etidronate; Pain

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL INHIBITOR; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GLIBENCLAMIDE; INDOMETACIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MESSENGER RNA; POTASSIUM CHANNEL BLOCKING AGENT; RECEPTOR SUBUNIT; SULFONYLUREA RECEPTOR 1; SULFONYLUREA RECEPTOR 2A; SULFONYLUREA RECEPTOR 2B; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDEMA; MALE; MEMBRANE CHANNEL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; SPINAL GANGLION;

ADENOSINE TRIPHOSPHATE; ALENDRONATE; ANALGESICS; ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY CONSERVATION AGENTS; EDEMA; ETIDRONIC ACID; GANGLIA, SPINAL; MALE; PAIN MEASUREMENT; PHYSICAL STIMULATION; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PROTEIN SUBUNITS; RATS; RATS, INBRED LEW; RNA, MESSENGER;

EID: 33745951001     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.03.015     Document Type: Article

References (31)

1. Adami S. Bisphosphonates in prostate carcinoma. Cancer 80 (1997) 1674-1679
2. Adami S., Fossaluzza V., Gatti D., Fracassi E., and Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann. Rheum. Dis. 56 (1997) 201-204
3. Barrera P., Blom A., van Lent P.L., van Bloois L., Beijnen J.H., van Rooijen N., de Waal Malefijt M.C., van de Putte L.B., Storm G., and van den Berg W.B. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. 43 (2000) 1951-1959
4. Benford H.L., Frith J.C., Auriola S., Monkkonen J., and Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56 (1999) 131-140
5. Bonabello A., Galmozzi M.R., Bruzzese T., and Zara G.P. Analgesic effect of bisphosphonates in mice. Pain 91 (2001) 269-275
6. Bonabello A., Galmozzi M.R., Canaparo R., Serpe L., and Zara G.P. Long-term analgesic effect of clodronate in rodents. Bone 33 (2003) 567-574
7. + channels in rat vascular smooth muscles. Biochem. Biophys. Res. Commun. 296 (2002) 463-469
8. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., and Wang K.K. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335 (1996) 1016-1021
9. Forys V.A. Etidronate and osteoarthritis. Jama 265 (1991) 2807
10. Goicoechea C., Porras E., Alfaro M.J., and Martin M.I. Alendronate induces antinociception in mice, not related with its effects in bone. Jpn. J. Pharmacol. 79 (1999) 433-437
11. Goldring S.R., and Gravallese E.M. Bisphosphonates: environmental protection for the joint?. Arthritis Rheum. 50 (2004) 2044-2047
12. Harada H., Nakayama T., Nanaka T., and Katsumata T. Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflamm. Res. 53 (2004) 45-52
13. Kato S., Ogawa Y., Kanatsu K., Okayama M., Watanabe T., Arakawa T., and Takeuchi K. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J. Pharmacol. Exp. Ther. 303 (2002) 503-509
14. Kawabata A., Kawao N., Kuroda R., Tanaka A., Itoh H., and Nishikawa H. Peripheral PAR-2 triggers thermal hyperalgesia and nociceptive responses in rats. Neuroreport 12 (2001) 715-719
15. Kubalek I., Fain O., Paries J., Kettaneh A., and Thomas M. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford) 40 (2001) 1394-1397
16. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
17. + channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides. Eur. J. Pharmacol. 385 (1999) 119-127
18. Oelzner P., Kunze A., Henzgen S., Thoss K., Hein G., Stein G., and Brauer R. High-dose clodronate therapy prevents joint destruction in chronic antigen-induced arthritis of the rat but inhibits bone formation at the axial skeleton. Inflamm. Res. 49 (2000) 424-433
19. + channels. Eur. J. Pharmacol. 512 (2005) 23-28
20. + channels mediates the antinociceptive effect of Crotalus durissus terrificus snake venom. Eur. J. Pharmacol. 469 (2003) 57-64
21. Proks P., Reimann F., Green N., Gribble F., and Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 51 Suppl. 3 (2002) S368-S376
22. + current. J. Cell. Mol. Med. 6 (2002) 271-274
23. + channel pathway. Proc. Natl. Acad. Sci. USA 101 (2004) 3680-3685
24. Sahni M., Guenther H.L., Fleisch H., Collin P., and Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91 (1993) 2004-2011
25. Saito J., Ozaki Y., Ohnishi H., Nakamura T., and Ueta Y. Induction of galanin-like peptide gene expression in the rat posterior pituitary gland during endotoxin shock and adjuvant arthritis. Brain Res. Mol. Brain Res. 113 (2003) 124-132
26. Sarantopoulos C., McCallum B., Sapunar D., Kwok W.M., and Hogan Q. ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin. Neurosci. Lett. 343 (2003) 185-189
27. + channels in the rat PGE2-induced hyperalgesic paw. Br. J. Pharmacol. 134 (2001) 127-131
28. Storm T., Thamsborg G., Steiniche T., Genant H.K., and Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322 (1990) 1265-1271
29. Takasaki K., Nakajima T., Ueno K., Nomoto Y., and Higo K. Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. J. Pharmacol. Sci. 95 (2004) 291-293
30. Varenna M., Zucchi F., Ghiringhelli D., Binelli L., Bevilacqua M., Bettica P., and Sinigaglia L. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J. Rheumatol. 27 (2000) 1477-1483
31. + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am. J. Physiol. 274 (1998) C25-C37